Skip to main content

Table 4 Association of independent factors with metabolic syndrome among HIV infected patients using ART at Hawassa, southern Ethiopia

From: Influences of gender in metabolic syndrome and its components among people living with HIV virus using antiretroviral treatment in Hawassa, southern Ethiopia

Explanatory variable

Metabolic syndrome by using IDF criteria

Metabolic syndrome by using NCEP-ATP criteria

Presence of MetS = N (%)

COR (95 % CI)

AOR (95 % CI)

Presence of MetS = N (%)

COR (95 % CI)

AOR (95 % CI)

BMI (kg/m2)

 ≤25

30 (16.2)

1.00

1.00

21 (11.3)

1.00

1.00

 >25

15 (8.1)

3.0 (1.3–6.5)

3.8 (1.5–9.8)

12 (6.5)

3.2 (1.4–7.4)

3.4 (1.3–9.2)

 p value

 

0.006

0.005

 

0.006

0.01

Gender

 Male

6 (3.2)

1.00

1.00

12 (6.5)

1.00

1.00

 Female

39 (21.1)

5.1 (2.0–12.9)

7.9 (2.6–24.1)

21 (11.3)

1.0 (0.47–2.3)

1.5 (0.24–1.8)

 p value

 

<0.0001

<0.0001

 

0.19

0.43

Age (years)

 ≤40

41 (22.1)

1.00

1.00

25 (13.5)

1.00

1.00

 >40

4 (2.1)

0.66 (0.21–2.0)

2.0 (0.45–9.5)

8 (4.3)

3.1 (1.2–8.3)

3.8 (1.0–13.7)

 p value

 

0.21

0.35

 

0.02

0.04

ART use (months)

 ≤48

22 (11.9)

1.00

1.00

20 (10.8)

1.00

1.00

 >48

23 (12.4)

1.8 (0.95–3.7)

2.3 (1.0–5.4)

13 (7.0)

0.99 (0.46–2.1)

0.8 (0.32–1.9)

 p value

 

0.07

0.04

 

0.20

0.33

Cigarette

 Never smoke

43 (23.2)

1.00

1.00

28 (15.1)

1.00

1.00

 Still smoking

2 (1.1)

0.26 (0.06–1.1)

0.17 (0.03–1.0)

5 (2.7)

1.3 (0.45–3.9)

0.47 (0.10–2.1)

 p value

 

0.08

0.05

 

0.18

0.33

Education

 Illiterate

1 (0.5)

1.00

1.00

3 (1.6)

1.00

1.00

Primary

22 (11.9)

6.7 (0.8–53.3)

10.1 (1.1–94)

15 (8.1)

1.2 (0.31–4.7)

0.85 (0.17–4.3)

 p value

 

0.07

0.04

 

0.16

0.24

Secondary and above

22 (11.9)

6.2 (0.79–49.9)

10.9 (1.1–104)

15 (8.1)

1.1 (0.3–4.4)

1.1 (0.45–2.8)

 p value

 

0.08

0.04

 

0.21

0.37

  1. ART antiretroviral therapy, COR crude odds ratio, AOR adjusted odds ratio, CI confidence interval, BMI body mass index, EFV Efavirenz, NVP Nevirapine, NNRTI non nucleoside reverse transcriptase inhibitors